Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement

Takeshi Oda; Ryusuke Mori; Eiki Tayama; Shigeaki Aoyagi

doi:doi:10.11648/j.ijcts.20230904.13

| Peer-Reviewed

Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement

Takeshi Oda, Ryusuke Mori, Eiki Tayama, Shigeaki Aoyagi

Published in International Journal of Cardiovascular and Thoracic Surgery (Volume 9, Issue 4)

Received: 25 July 2023 Accepted: 10 August 2023 Published: 22 August 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.

Published in	International Journal of Cardiovascular and Thoracic Surgery (Volume 9, Issue 4)
DOI	10.11648/j.ijcts.20230904.13
Page(s)	56-62
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Landiolol, POAF, AVR

References

[1]	Creswell LL, Schuessler RB, Rosenbloom M, et al. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993; 56: 539-49.
[2]	Shen J, Lall Shelly, Zheng V, et al. The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. J Thorac Cardiovasc Surg. 2011; 141: 559-70.
[3]	Greenberg JW, Lancaster TS, Schuessler RB, et al. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. 2017; 52: 665-72.
[4]	Woldendorp K, Farag J, Khadra S, et al. Postoperative atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg. 2021; 112: 2084-93.
[5]	Eikelboom R, Sanjanwala R, Le ML, et al. Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg. 2021; 111: 544-55.
[6]	Filardo G, Damiano RJ Jr, Ailawadi G, et al. Epidemiology of new-onset atrial fibrillation following coronary artery bypass graft surgery. Heart. 2018; 104: 985-92.
[7]	Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2015; 48: 817-24.
[8]	White CM, Kluger J, Lertsburapa K, et al. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg. 2007; 31: 717-20.
[9]	Tamura K, Arai H, Ito F, et al. Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation. Gen Thorac Cardiovasc Surg. 2010; 58: 120-5.
[10]	Mclntyre WF. Post-operative atrial fibrillation after cardiac surgery: challenges throughout the patient journey. Front Cardiovasc Med. 2023; DOI: 10.3389/fcvm.2023.1156626.
[11]	Fujiwara H, Sakurai M, Namai A, et al. Effect of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation after CABG surgery. Gen Thorac Cardiovasc Surg. 2009; 57: 132-7.
[12]	Sezai A, Minimi K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011; 141: 1478-87.
[13]	Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012; 144: 1241-8.
[14]	Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg. 2012; 53: 369-74.
[15]	Osumi M, Tashiro T, Morita Y, et al. Preventive effect of intraoperative landiolol administration on atrial fibrillation after off-pump coronary artery bypass grafting. Adv Ther. 2014; 31: 1109-17.
[16]	Nagaoka E, Arai H, Tamura K, et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg. 2014; 20: 129-34.
[17]	Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012; 53: 359-63.
[18]	Yokota J, Nishi H, Sekiya N, et al. Atrial fibrillation following aortic valve replacement: impact of perioperative use of intravenous β-blocker. Gen Thorac Cardiovasc Surg. 2017; 65: 194-9.
[19]	Filardo G, Hamilton C, Hamman B, et al. New-onset postoperative atrial fibrillation and long-term survival after aortic valve replacement surgery. Ann Thorac Surg. 2010; 90: 474-80.
[20]	Banach, M, Goch A, Misztal M, et al. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2007; 134: 1569-76.
[21]	Kaireviciute D, Aidietis A, Lip G YH, et al. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J. 2009; 30: 410-25.
[22]	Kalman JM, Munawar M, Howes LG, et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg. 1995; 60: 1709-15.
[23]	Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. Adv Ther. 2014; 31: 440-50.
[24]	Shahim B, Malaisrie C, George I, et al. Postoperative atrial fibrillation or flutter following transcatheter or surgical aortic valve replacement. J Am Coll Cardiol Intv. 2021; 14: 1565-74.
[25]	Okamura H, Arakawa M, Miyagawa A, Adachi H. Incidence of postoperative atrial fibrillation in transdermal beta-blocker patch users is lower than that in oral beta-blocker users after cardiac and/or thoracic aortic surgery. Gen Thorac Cardiovasc Surg. 2019; 67: 1007-13.

Cite This Article

Plain Text BibTeX RIS

APA Style

Takeshi Oda, Ryusuke Mori, Eiki Tayama, Shigeaki Aoyagi. (2023). Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. International Journal of Cardiovascular and Thoracic Surgery, 9(4), 56-62. https://doi.org/10.11648/j.ijcts.20230904.13

Copy | Download

ACS Style

Takeshi Oda; Ryusuke Mori; Eiki Tayama; Shigeaki Aoyagi. Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. Int. J. Cardiovasc. Thorac. Surg. 2023, 9(4), 56-62. doi: 10.11648/j.ijcts.20230904.13

Copy | Download

AMA Style

Takeshi Oda, Ryusuke Mori, Eiki Tayama, Shigeaki Aoyagi. Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. Int J Cardiovasc Thorac Surg. 2023;9(4):56-62. doi: 10.11648/j.ijcts.20230904.13

Copy | Download

@article{10.11648/j.ijcts.20230904.13,
  author = {Takeshi Oda and Ryusuke Mori and Eiki Tayama and Shigeaki Aoyagi},
  title = {Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement},
  journal = {International Journal of Cardiovascular and Thoracic Surgery},
  volume = {9},
  number = {4},
  pages = {56-62},
  doi = {10.11648/j.ijcts.20230904.13},
  url = {https://doi.org/10.11648/j.ijcts.20230904.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcts.20230904.13},
  abstract = {Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement
AU  - Takeshi Oda
AU  - Ryusuke Mori
AU  - Eiki Tayama
AU  - Shigeaki Aoyagi
Y1  - 2023/08/22
PY  - 2023
N1  - https://doi.org/10.11648/j.ijcts.20230904.13
DO  - 10.11648/j.ijcts.20230904.13
T2  - International Journal of Cardiovascular and Thoracic Surgery
JF  - International Journal of Cardiovascular and Thoracic Surgery
JO  - International Journal of Cardiovascular and Thoracic Surgery
SP  - 56
EP  - 62
PB  - Science Publishing Group
SN  - 2575-4882
UR  - https://doi.org/10.11648/j.ijcts.20230904.13
AB  - Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.
VL  - 9
IS  - 4
ER  -

Copy | Download

Author Information

Takeshi Oda

Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Ryusuke Mori

Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Eiki Tayama

Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
Shigeaki Aoyagi

Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Takeshi Oda, Ryusuke Mori, Eiki Tayama, Shigeaki Aoyagi. (2023). Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. International Journal of Cardiovascular and Thoracic Surgery, 9(4), 56-62. https://doi.org/10.11648/j.ijcts.20230904.13

Copy | Download

ACS Style

Takeshi Oda; Ryusuke Mori; Eiki Tayama; Shigeaki Aoyagi. Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. Int. J. Cardiovasc. Thorac. Surg. 2023, 9(4), 56-62. doi: 10.11648/j.ijcts.20230904.13

Copy | Download

AMA Style

Takeshi Oda, Ryusuke Mori, Eiki Tayama, Shigeaki Aoyagi. Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement. Int J Cardiovasc Thorac Surg. 2023;9(4):56-62. doi: 10.11648/j.ijcts.20230904.13

Copy | Download

@article{10.11648/j.ijcts.20230904.13,
  author = {Takeshi Oda and Ryusuke Mori and Eiki Tayama and Shigeaki Aoyagi},
  title = {Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement},
  journal = {International Journal of Cardiovascular and Thoracic Surgery},
  volume = {9},
  number = {4},
  pages = {56-62},
  doi = {10.11648/j.ijcts.20230904.13},
  url = {https://doi.org/10.11648/j.ijcts.20230904.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcts.20230904.13},
  abstract = {Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Administration of Low-Dose Landiolol Prevents Postoperative Atrial Fibrillation After Aortic Valve Replacement
AU  - Takeshi Oda
AU  - Ryusuke Mori
AU  - Eiki Tayama
AU  - Shigeaki Aoyagi
Y1  - 2023/08/22
PY  - 2023
N1  - https://doi.org/10.11648/j.ijcts.20230904.13
DO  - 10.11648/j.ijcts.20230904.13
T2  - International Journal of Cardiovascular and Thoracic Surgery
JF  - International Journal of Cardiovascular and Thoracic Surgery
JO  - International Journal of Cardiovascular and Thoracic Surgery
SP  - 56
EP  - 62
PB  - Science Publishing Group
SN  - 2575-4882
UR  - https://doi.org/10.11648/j.ijcts.20230904.13
AB  - Background: Postoperative atrial fibrillation (POAF), a common complication of cardiac surgery, increases postoperative mortality, morbidity, and medical costs. POAF after coronary artery bypass grafting is well investigated; however, little is known about POAF after aortic valve replacement (AVR). This study aimed to investigate the efficacy of low-dose landiolol in preventing POAF after AVR. Methods: Thirty patients who underwent AVR were randomized into two groups, with or without administration of landiolol (Landiolol, N=15; Control, N=15). In Landiolol, continuous infusion of landiolol (3 µg/kg/min) was maintained for 48 h from admission to the intensive care unit. The occurrence of POAF during seven days after surgery, heart rate, blood pressure, cardiac index, and mixed venous oxygen saturation were compared between the two groups. Results: POAF occurred in one and seven patients in Landiolol (6.7%) and Control (46.7%), respectively, with significantly lower incidence in Landiolol than in Control (p=0.0352). The heart rate was significantly lower in Landiolol than in Control. No significant differences were observed in blood pressure, cardiac indices, and mixed venous hemoglobin oxygen between the two groups. Conclusions: The administration of low-dose landiolol following AVR significantly decreased the incidence of POAF without hemodynamic deterioration, suggesting that it may safely and effectively prevent POAF in patients undergoing AVR.
VL  - 9
IS  - 4
ER  -

Copy | Download